CorMedix Inc. (NASDAQ:CRMD) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET
Company Participants
Joe Todisco - Chief Executive Officer
Matt David - Executive Vice President, Chief Financial Officer
Phoebe Mounts - Executive Vice President, General Counsel
Erin Mistry - Senior Vice President, Commercial
Daniel Ferry - LifeSci Advisors
Conference Call Participants
Assam - Truist Securities
Jason Butler - JMP Securities
Serge Belanger - Needham & Co.
Operator
Good morning and welcome to the CorMedix Inc. third quarter 2022 earnings conference call.
At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require Operator assistance during the conference, please press star, zero on your telephone keypad. As a reminder, this conference is being recorded.
It is now my pleasure to introduce your host, Daniel Ferry from LifeSci Advisors. Thank you and over to you.
Daniel Ferry
Good morning and welcome to the CorMedix third quarter 2022 earnings conference call. Leading the call today is Joe Todisco, Chief Executive Officer of CorMedix, and he is joined by Dr. Matt David, Executive Vice President and CFO, Dr. Phoebe Mounts, EVP, General Counsel and Head of Technical Operations, and Erin Mistry, SVP of Commercial.
Before we begin, I would like to remind everyone during the call, management may make what are known as forward-looking statements within the meaning set forth in the Private Securities Litigation Reform Act of 1995. These statements are subject to certain risks and uncertainties and include but are not limited to any of the following: any statements, other than statements of historical fact regarding management’s expectations, beliefs, goals, and plans about the company’s prospects, including its clinical development program, manufacturing activities, and NDA approval for DefenCath in the U.S. or other product candidates, future financial position, future revenues and projected costs, and potential market acceptance of DefenCath or other product candidates.
More specifically, forward-looking statements include any statements about our clinical development plans and the timing, costs, progress, results, estimates and interpretations thereof, projections as to the company’s future capital raising, spending and cash position, expectations as to the timing and nature of anticipated regulatory actions, possible product licensing, business development or other transactions, any commercial plans and expectations, market projections for our current product candidates, and expectations as to manufacturing and product component costs.
Actual results may differ materially from these projections or estimates due to a variety of important factors, including but not limited to uncertainties related to clinical development, regulatory approvals and commercialization. These risks are described in greater detail in CorMedix’s filings with the SEC, including the latest 10-Q filing, copies of which are available free of charge at the SEC’s website at www.sec.gov or upon request from CorMedix. CorMedix may not actually achieve the goals or plans described in these forward-looking statements and investors should not place undue reliance on these statements. Please note that CorMedix does not intend to update these forward-looking statements except as required by law.